{"name":"Fractyl Health","slug":"fractyl","ticker":"GUTS","exchange":"NASDAQ","domain":"fractyl.com","description":"Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).","hq":"Lexington, MA","founded":0,"employees":"","ceo":"Harith Rajagopalan, MD, PhD","sector":"Metabolic Disease / Medical Devices","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":2.2,"rdSpend":74536000,"netIncome":-140954000,"cash":81540000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Fractyl Health reported fourth quarter and full year 2023 financial results, with revenue of $10.3 million and a net loss of $43.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Fractyl Health Announces Collaboration with Leading Academic Institution","summary":"Fractyl Health announced a collaboration with a leading academic institution to advance the development of its Elva system.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxORkppWDdGekpWQ1dZWGRtVzdmaDc0ZW42cGkxYkVPb19pTEVnNTRKTFk4MXFIUDMyZklNakNNckYwNjFaWVlsOVY0T3BqdURMYUMwTmg2MDFNdVdpV3BKNi1pc3BKY3pMdDZXOHluWDdZZ1BQVWw0bURJSXVjeXN2Z1BtVzBseGlHYWlTWDBhOFUxZWh3TXBKdU1nNUE2MmNWek56eE9CMThvWFBWWGVnUTNvc2FCLXRScmthOW91ZFlZdV91TlB0QW9waW5WOU90Mkl6LXpGTHYtbWhDSUVRbm5uYlNaNC11ZmZoNFYxVWtBSXpvc0NhOXU3RUZKWFRsZzhyU0Jjc0Q3c2NiOHIzR0NVMzI?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdjB5clRGWEFqc3JIUFF0NGFaWUhtclpSc1paWkRDMnJBRUpuZDdqbzBnc1N4Sy1ROUYtVVZIbi1ZTXBGZFAzRUp1V2NIcG5EdjdxWnVlYzZ0RmU1N2t4UUoxNmZqOVNGcEZSdGd0U0poOTBRZ1pUMzMweDFyX1p4M3ktcEFjUmlPSVoySEdyRVpCSUctLWF4TEQ5MTZ2NDMxeDRHUFdueXY?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans - Stock Titan","headline":"Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans","sentiment":"neutral"},{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-22","type":"deal","source":"MSN","summary":"Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag - MSN","headline":"Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOU3JkX1ZqLWxXN0FjMGZYSFB2NmktN3diaUZKWkJkZ2JvakwycDVJSnpBSUFINUhyaVhTcmM2OEdJTUdEcTRWR0gzVzRORVZHVFBxVlEtOWVOSkgtYzVVOXdIZjNKNkdUdnhCaUx5Um42RWdNdkM4c3JyTXh4bGhCeHlvWHRmZEIyM0lFYzRjUF9KM25WYlIzVFRrVlVQb3RxVDMyN2tYa2ZPQlJMNjBzbThEQXVJTk9ydjBPVWJHTV8?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Fractyl Health sets March 24 call on 2025 results, business updates - Stock Titan","headline":"Fractyl Health sets March 24 call on 2025 results, business updates","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOM2prZ1pGYzY5M1FTZHRXNnFmakhCd1BtM3FMYlVfTjNOZ2JHS0ttSjJLclhjaG9GQnZIQUNfZ1NiVThDZ2U2S19xaEhGT3lQSHNwdDlaRzNzcWZsd2pNQVEtZllOSzljbU5LQjkyS2dpellSWHIyMWZMUXRPeWZySFRiVXVJVk9lcXdXaDRlX3pfVTJTSVozYTBJMTAycGgwbWs4RFpaQ1o5SHVm?oc=5","date":"2026-02-04","type":"trial","source":"BioCentury","summary":"Even endpoint hits don’t spare shares in three weight-loss updates - BioCentury","headline":"Even endpoint hits don’t spare shares in three weight-loss updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNlFHSWVqRi1IbC1DbjROamtfYmRDZjduaDZkQlpnSTY3UHJ2a2xNZzR1Zkl2OGtkZFktLUVva2J0UEMyOURsN0l2ZVlFY1JXdVUtODBhMHNfYm5ZRWJ5RUlmVmlFcHdOSUlid0pzbnByemxKSUZudlBnMmNwQmpMOWs5TENkN2JaWWV2QjhVUEgwVUVzMWwyMGtJeExkUWdHMm11N1JUZk5fbFpHTVVKb0x2ZWZZdDM0RmpUSDZB?oc=5","date":"2026-02-02","type":"pipeline","source":"Seeking Alpha","summary":"Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts - Seeking Alpha","headline":"Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQTFdYYjRPd3ZtTXIzZktDZUtxMm9kUFZLM1g1TzJVUk4yUUFFbm0tWWJGOGlFMVQtay1MbHZHUnJhZEYyNGhVX055Rzg3aFBCQXlnZXRZZkJPaG9zeEVaOVBNMlY3YkhNRnFrdGFQTnI0NGZPWWpLa3R3bkxReDh0UGtqYjBXNENSWEtxa1BCVG1vbU53S1pDNWJ3SnFQdw?oc=5","date":"2026-01-29","type":"trial","source":"Seeking Alpha","summary":"Fractyl Health plummets on data for Revita for weight loss maintenance - Seeking Alpha","headline":"Fractyl Health plummets on data for Revita for weight loss maintenance","sentiment":"positive"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNF8yRVVRdmFIVnN4aUFZOXpLSzhrUU1nZE1Wd241MllMMldSMVROMmduVHJKa1lEZS1kMFQ3MTIzcXhBTVVOR1RCSGZWRk1ZMXFraTRZTmNYODc1dEY4VGdUelUxM0pnWWVwd09LaHpOd0xOUGd3OWZ4eV9JODNWYnVUd1ZkMkZleGd3?oc=5","date":"2025-12-31","type":"pipeline","source":"The Business Journals","summary":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals","headline":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Medtronic","Boston Scientific","Abbott Laboratories"],"therapeuticFocus":["Metabolic Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":43000,"grossProfitHistory":[],"rdSpend":74536000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-140954000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":81540000,"cashHistory":[],"totalAssets":121402000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}